CA3008993A1 - Aromatic-cationic peptides and uses of same - Google Patents

Aromatic-cationic peptides and uses of same Download PDF

Info

Publication number
CA3008993A1
CA3008993A1 CA3008993A CA3008993A CA3008993A1 CA 3008993 A1 CA3008993 A1 CA 3008993A1 CA 3008993 A CA3008993 A CA 3008993A CA 3008993 A CA3008993 A CA 3008993A CA 3008993 A1 CA3008993 A1 CA 3008993A1
Authority
CA
Canada
Prior art keywords
peptide
aromatic
lys
arg
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3008993A
Other languages
English (en)
French (fr)
Inventor
Hazel H. Szeto
Peter W. Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Original Assignee
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherches Cliniques de Montreal IRCM, Cornell University filed Critical Institut de Recherches Cliniques de Montreal IRCM
Publication of CA3008993A1 publication Critical patent/CA3008993A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3008993A 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same Abandoned CA3008993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
CA2787331A CA2787331A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2787331A Division CA2787331A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Publications (1)

Publication Number Publication Date
CA3008993A1 true CA3008993A1 (en) 2011-07-28

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3008993A Abandoned CA3008993A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same
CA2787331A Abandoned CA2787331A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2787331A Abandoned CA2787331A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Country Status (8)

Country Link
US (6) US20120329730A1 (enExample)
EP (4) EP3018138A1 (enExample)
JP (2) JP2013518057A (enExample)
CN (2) CN102834408A (enExample)
AU (2) AU2011207432A1 (enExample)
CA (2) CA3008993A1 (enExample)
HK (1) HK1208686A1 (enExample)
WO (1) WO2011091357A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017117381A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
JP7038675B2 (ja) 2016-03-11 2022-03-18 ステルス バイオセラピューティクス インコーポレイテッド 結晶塩形態
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
AU2019401254B2 (en) * 2018-12-18 2025-05-01 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0273696A2 (en) * 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
JPH04502629A (ja) * 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2713150C (en) * 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury

Also Published As

Publication number Publication date
AU2011207432A1 (en) 2012-08-02
WO2011091357A1 (en) 2011-07-28
EP2528934A4 (en) 2013-08-21
US20190330272A1 (en) 2019-10-31
US20170008925A1 (en) 2017-01-12
CN104725472A (zh) 2015-06-24
US20130316964A1 (en) 2013-11-28
JP2013518057A (ja) 2013-05-20
CA2787331A1 (en) 2011-07-28
CN102834408A (zh) 2012-12-19
US20180244721A1 (en) 2018-08-30
US20120329730A1 (en) 2012-12-27
EP2848628A1 (en) 2015-03-18
EP3018138A1 (en) 2016-05-11
AU2016200747A1 (en) 2016-02-25
US20150005242A1 (en) 2015-01-01
EP2733150A1 (en) 2014-05-21
HK1208686A1 (en) 2016-03-11
EP2528934A1 (en) 2012-12-05
JP2016000750A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
US11083772B2 (en) Methods and compositions for the prevention or treatment of Barth Syndrome
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
EP3586864A1 (en) Methods for the prevention or treatment of left ventricle remodeling
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
WO2017093897A1 (en) Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
HK1179977A (en) Aromatic-cationic peptides and uses of same
WO2016004441A1 (en) Methods for the prevention or treatment of acute myocardial infarction injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181211

FZDE Discontinued

Effective date: 20210315